Literature DB >> 29174309

Lung cancer's real adjuvant EGFR targeted therapy questions.

Terry L Ng1, D Ross Camidge2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29174309     DOI： 10.1016/S1470-2045(17)30875-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

Authors:  Yalei Zhang; Jianfei Shen; Charles B Simone; Federico Cappuzzo; Kwun M Fong; Rafael Rosell; Joe Y Chang; Luca Ampollini; J Isabelle Choi; Jianxing He; Tao Jiang
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 2.  Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer.

Authors:  Fabrizio Tabbò; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 3.  Liquid Biopsy to Identify Actionable Genomic Alterations.

Authors:  Sai-Hong Ignatius Ou; Misako Nagasaka; Viola W Zhu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 4.  Targeted Therapy in Early Stage Non-small Cell Lung Cancer.

Authors:  Si-Yang Liu; Si-Yang Maggie Liu; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Curr Treat Options Oncol       Date:  2022-07-25

5.  Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Authors:  Shannon S Zhang; Sai-Hong Ignatius Ou
Journal:  Lung Cancer (Auckl)       Date:  2022-04-26

6.  Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.

Authors:  Jianjiao Ni; Tiantian Guo; Yuan Li; Xi Yang; Yida Li; Liqing Zou; Li Chu; Xiao Chu; Shuyan Li; Luxi Ye; Yawei Zhang; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 7.  Role of circulating tumor DNA in the management of early-stage lung cancer.

Authors:  Heng Zhao; Ke-Zhong Chen; Ben-Gang Hui; Kai Zhang; Fan Yang; Jun Wang
Journal:  Thorac Cancer       Date:  2018-03-12       Impact factor: 3.500

8.  Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.

Authors:  Si-Yang Liu; Hua Bao; Qun Wang; Wei-Min Mao; Yedan Chen; Xiaoling Tong; Song-Tao Xu; Lin Wu; Yu-Cheng Wei; Yong-Yu Liu; Chun Chen; Ying Cheng; Rong Yin; Fan Yang; Sheng-Xiang Ren; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Song Dong; Xu-Chao Zhang; Jian Su; Jin-Ji Yang; Xue-Ning Yang; Qing Zhou; Xue Wu; Yang Shao; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Nat Commun       Date:  2021-11-08       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.